Hairy leukoplakia: Arm unusual combination of transforming and permissive Epstein-Barr virus infections

被引:69
作者
Webster-Cyriaque, J
Middeldorp, J
Raab-Traub, N
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Sch Dent, Dept Dent Ecol, Chapel Hill, NC 27599 USA
[4] Organon Tekn, Boxtel, Netherlands
关键词
D O I
10.1128/JVI.74.16.7610-7618.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human herpesviruses are characterized by distinct states of infection. Typically in permissive herpesvirus infection, abundant virus production results in cell lysis, In latent transforming Epstein-Barr virus (EBV) infection, viral proteins that induce cell growth are expressed. The immunodeficiency-associated hairy leukoplakia (HLP) lesion is the only pathologic manifestation of permissive EBV infection; however, within HLP, viral proteins characteristic of latent infection have also been detected. In this study, we further analyzed expression of EBV latent genes and investigated their contribution to the unique histologic phenotype of HLP. Coexpression of lytic and transforming viral proteins was detected simultaneously within individual HLP keratinocytes, LMP1 has now been shown to be uniformly expressed in the affected tissue, and it is associated and colocalizes with tumor necrosis factor receptor-associated factor (TRAF) signaling molecules. Effects induced by activated TRAF signaling that were detected in HLP included activation of NF-kappa B and c-Jun terminal kinase 1 (JNK1) and upregulated expression of epidermal growth factor receptor (EGFR), CD40, A20, and TRAPs. This study identifies a novel state of EBV infection with concurrent expression of replicative and transforming proteins. It is probable that both replicative and latent proteins contribute to BLP development and induce many of the histologic features of HLP, such as acanthosis and hyperproliferation. In contrast to other permissive herpesvirus infections, expression of EBV transforming proteins within the permissively infected HLP tissue enables epithelial cell survival and may enhance viral replication.
引用
收藏
页码:7610 / 7618
页数:9
相关论文
共 45 条
[11]   Epidermal differentiation [J].
Fuchs, E. .
CURRENT OPINION IN CELL BIOLOGY, 1990, 2 (06) :1028-1035
[12]   THE EPIDERMIS - RISING TO THE SURFACE [J].
FUCHS, E ;
BYRNE, C .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1994, 4 (05) :725-736
[13]   EPSTEIN-BARR-VIRUS SMALL NUCLEAR RNAS ARE NOT EXPRESSED IN PERMISSIVELY INFECTED-CELLS IN AIDS-ASSOCIATED LEUKOPLAKIA [J].
GILLIGAN, K ;
RAJADURAI, P ;
RESNICK, L ;
RAABTRAUB, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8790-8794
[14]   ORAL LESIONS MIMICKING HAIRY LEUKOPLAKIA - A DIAGNOSTIC DILEMMA [J].
GREEN, TL ;
GREENSPAN, JS ;
GREENSPAN, D ;
DESOUZA, YG .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1989, 67 (04) :422-426
[15]   REPLICATION OF EPSTEIN-BARR VIRUS WITHIN THE EPITHELIAL-CELLS OF ORAL HAIRY LEUKOPLANKIA, AN AIDS-ASSOCIATED LESION [J].
GREENSPAN, JS ;
GREENSPAN, D ;
LENNETTE, ET ;
ABRAMS, DI ;
CONANT, MA ;
PETERSEN, V ;
FREESE, UK .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (25) :1564-1571
[16]   Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation [J].
Harada, S ;
Kieff, E .
JOURNAL OF VIROLOGY, 1997, 71 (09) :6611-6618
[17]   EPSTEIN-BARR VIRUS-CODED BHRF1 PROTEIN, A VIRAL HOMOLOG OF BCL-2, PROTECTS HUMAN B-CELLS FROM PROGRAMMED CELL-DEATH [J].
HENDERSON, S ;
HUEN, D ;
ROWE, M ;
DAWSON, C ;
JOHNSON, G ;
RICKINSON, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8479-8483
[18]  
HUEN DS, 1995, ONCOGENE, V10, P549
[19]   Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade [J].
Kieser, A ;
Kilger, E ;
Gires, O ;
Ueffing, M ;
Kolch, W ;
Hammerschmidt, W .
EMBO JOURNAL, 1997, 16 (21) :6478-6485
[20]  
KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354